Our lead pipeline product is IBI-10090 which is being developed as a sustained-released therapy for inflammation associated with cataract surgery. An estimated 3 million or more cataract surgeries are performed annually in the U.S. alone.
This product employs Icon’s Verisome drug delivery platform to dispense a long-acting, biodegradable formulation of the anti-inflammatory agent dexamethasone into the anterior chamber of the eye through a single injection administered immediately following surgery. IBI-10090 has been specifically designed to deliver a controlled release of the active agent over a sufficient time to provide an alternative to the current standard treatment regimen involving a comparatively burdensome process of patient administered eye drops applied topically several times daily for an extended period of time.
IBI-10090 is well advanced into a pivotal Phase 3 randomized, double blind, and placebo-controlled study. A previous Phase 2/3 study demonstrated a favorable efficacy and safety profile.
More information can be found on clinicaltrials.gov.